However, current research on the role of the gut microbiota in GC immunotherapy remains limited, and further studies are needed to explore the potential relationship between the gut microbiome and PD‐1/PD‐L1 inhibitors in GC treatment. This evidence concerns the gene PDCD1 and gastric cancer.